AVONEX 30 micrograms/0.5ml solution for injection in pre-filled pen.
Sponsors
Biogen Idec Research Limited, Les Hopitaux Universitaires De Strasbourg
Conditions
Multiple SclerosisRelapsing Remitting Multiple Sclerosis (RRMS)
Phase 3
DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL - TWINS
RecruitingCTIS2024-513475-41-00
Start: 2025-02-03Target: 200Updated: 2024-11-08
An Open Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less than 18 Years for the Treatment of Relapsing Remitting Multiple Sclerosis, with Optional Open-Label Extension (105MS306)
Active, not recruitingCTIS2023-505624-56-00
Start: 2019-08-07Target: 29Updated: 2025-09-11